Pharmaceutical Executive
KOLs have traditionally exerted their influence through research and publication on drug safety and efficacy, but now share the stage with other important measures.
Paul Chew, MD
Advertisement
Articles by Paul Chew, MD
Pharmaceutical Executive
A discussion of the cost and time put into clinical trials.
Advertisement
Latest Updated Articles
- KOLs: An Endangered Buzzword
March 20th 2019
Advertisement
Advertisement
Trending on PharmExec
1
President Trump Planning to Fire FDA Commissioner Marty Makary: Report
2
GLP-1 Patent Expiry & the Rise of Generics: Transforming the Drug Delivery Device Landscape & Procurement Strategy
3
Factors Contributing to the Growth of Radiopharmaceuticals: Q&A with Andrea Zobel and Marco Hogenboom
4
FDA Extends Priority Review of Leqembi Iqlik Subcutaneous Injection
5